Arkolith/Insider Trading/ADMS/Form 4

McFarlane Neil F.

Chief Executive Officer, DirectorAdamas Pharmaceuticals Inc (ADMS) · full profile →Form 4 · filed Nov 24, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 24, 2021Grant(A)75K—$0600K
Nov 24, 2021Tender(U)600K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 24, 2021Disposed to issuer(D)200K——0
Nov 24, 2021Disposed to issuer(D)250K——0

Transaction Codes

A
Grant / award
U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001328143-21-000093) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML